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Introduction
In January 2002, the New England Journal of Medicine published a 
paper entitled “Migraine-Current Understanding and Treatment,” 
written by several leading neurologists. The paper reviewed 
all the current treatment options for migraine headaches, and 
strongly emphasized triptans, a relatively new class of drugs 
developed by drug companies specifically to address migraines 
(Goadsby et. al., 2002). One of the most notable aspects of the 
paper was that it completely omitted the drug class antiemetics, 
which is increasingly used nationally and internationally, mostly 
among emergency medicine practitioners, to treat acute migraine 
headaches (Seguil & Lax, 2014). One factor for this omission may 
have been the varied perspectives which can often develop be-
tween members of different specialties of medicine, with neu-
rologists recommending one therapy and emergency medicine 
doctors recommending another (Newman, 2009). Nevertheless, 
it is likely that the authors were aware of the therapeutic history 
of antiemetics for migraine headaches, and they chose to omit 
it. In fact, the papers recommendations are completely consis-
tent with the guidelines published by the American Academy of 
Neurology (n.d.). The purpose of this review is to assess whether 
these influential omissions are in fact warranted by clinical obser-
vation and meta-analysis, or if antiemetics should be considered 
an efficacious treatment for acute migraines with the right clinical 
indications. Possible biases that could have caused conscious or 
subconscious influences on the recommendations of different 
groups will also be analyzed as a method of understandings them.
Methods
In order to assess antiemetics as an efficacious treatment option 
for acute migraines, a meta-analysis of the published literature 
was undertaken. Comparative studies between the effectiveness 
of triptans and antiemetics is the main focus. In assessing clinical 
value, both primary effectiveness and secondary side-effect prev-
alence were surveyed to accurately portray an overall picture of 
patient outcomes. Clinical trials were obtained using the National 
Institute of Health’s PubMed search engine, and only studies pub-
lished in reputable academic journals were included.  
Migraine Headaches
A migraine headache is defined as a headache that usually affects 
one specific area or side of the head and is frequently accompa-
nied by nausea, sensory sensitivity, and possible neuralgia (Ferrari, 
2013). Headaches accompanied by neuralgia have been recorded 
since ancient times, as far back as the ancient Egyptians (Miller, 
et. al. 2005). The difference between a normal headache and a 
migraine is often one of degree and thus cannot always be defini-
tively assessed; however, chronicity can be an important indicator 
of migraines. The first modern treatment for migraines was er-
gotamine (Woakes, 1868), which was originally hypothesized to 
slow the stimulation of sympathetic nervous pathways (although 
its mechanism is now contested). The pathogenesis of migraines 
was illuminated in the 1940s, when serotonin was isolated as a 
potent cause of migraines (Wolff, 1948). This discovery led to the 
serotonin-inhibiting class of migraine treatments, starting with 
methylsergide, which was first used in the middle of the 20th 
century (Sicuteri, 1959).  
This paper focuses on two modern therapies for migraine head-
aches: triptans, of which the prototype drug is sumatriptan, dis-
covered in 1988, and antiemetics, which are primarily anti-nau-
sea medications, including domperidone, metoclopramide, and 
prochlorperazine. These drugs are typically given together with 
an analgesic, usually aspirin. Other commonly used pain-relieving 
drugs, such as NSAIDs, caffeine, and codeine should be noted, but 
are not of specific interest to this discussion.
Triptans
Triptans were first used in the treatment of migraines during the 
1980’s, when interest surged in examining the role of serotonin 
(5-HT) in the pathogenesis and pathophysiology of migraines 
(Bateman, 2000). Triptans are a class of drugs that affect sero-
tonin receptors, commonly called 5-HT receptors, of which there 
are many subtypes. Triptans are 5-HT agonists, binding with high 
affinity to many 5-HT subtypes that cause potent vasoconstric-
tion of many intracranial blood vessels. They also affect various 
neurotransmitters and chemical mediators, but no specific ef-
fect has been conclusively tied to theiranti-neuralgic properties. 
Because of a variety of concerns regarding the effectiveness of 
the original triptans, such as variable bioavailability, variable ab-
sorption, and significant adverse effects, new classes of triptans 
have been continuously developed by drug companies. Some of 
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the most recent triptans typically prescribed for migraine head-
aches include almotriptan, frovatriptan, and avitriptan (Loder, 
2010). Although the mechanism of the therapy remains unclear, it 
is generally recognized in the United States as a first-line therapy 
for patients unresponsive to analgesics. Triptans provide relief of 
symptoms within the first 10-60 minutes of use, depending on 
route of entry (Loder). 
Antiemetics
Antiemetics are drugs that relieve symptoms of vomiting and 
nausea. They are usually used to treat motion sickness and to 
relieve the side effects of nausea-causing therapies. The use of 
antiemetics as a direct therapy for migraine headaches was a 
serendipitous discovery. Originally, antiemetics were used to 
allow sufferers of migraines to ingest drugs given to relieve the 
headaches. However, physicians soon began to notice that the 
symptoms of the migraine headaches were relieved before the 
primary therapy could be given. Thus antiemetics soon became 
the drug of choice, especially among emergency medicine prac-
titioners, to treat analgesic-resistant headaches (Newman, 2009). 
Comparative Studies
Unfortunately, and for possible reasons that will be addressed 
further, there are very few studies that directly compare the 
efficaciousness of triptans and antiemetics in the treatment of 
migraine headaches (Gupta et. al., 2002). However, a number of 
studies have been completed globally that directly contrast these 
two treatment options.
The first comparative study was published in 1995, comparing 
oral sumatriptan (a triptan) with lysine acetylsalicylate plus me-
topramide (an aspirin plus an antiemetic) in their effectiveness 
in treating migraines (Tfelt-Hanson et. al., 1995). This study was 
conducted between October 26, 1993 and July 18, 1994 at over 
68 medical centers in Belgium, Denmark, the Netherlands, and 
France, and included only patients with significant histories of 
migraine headaches. It was a randomized, double-blind study, 
which included follow-up for up to as eight weeks, as needed. 
Four hundred twenty-one patients participated in the study. The 
study showed that in numerous benchmarks for effectiveness, 
the two treatment options were virtually identical, including im-
provement in immediate headache severity, control of adverse 
effects, headache recurrence, and patient satisfaction. The authors 
concluded that “there is no difference in primary or secondary 
efficacy between LAS+MTC and oral sumatriptan…because of 
its high price physicians should consider whether the routine use 
of sumatriptan as the initial treatment of a migraine attack really 
is preferable to the use of cheaper drugs such as analgesics com-
bined with an antiemetic.” Indeed, in Europe and in many other 
countries, these recommendations are generally considered best 
practice (Newman, 2009).
A subsequent study was performed in three medical centers in 
France, with a total of 666 participating patients (Geraud et. al., 
2002). It was a multicenter, double-blind, randomized study, and 
follow up was performed until fifteen days after the last migraine 
attack took place.  Each patient was given one of the follow-
ing: acetylsalicylic acid plus metoclopramide, zolmitriptan, or a 
placebo. The patients were then requested to keep an hourly 
diary to record headache relief, overall pain relief, nausea lev-
els, any adverse effects, and overall satisfaction with the thera-
py. The study results seemed to be inconclusive initially, as the 
authors wrote: “Both treatments reduced migraine-associated 
nausea, vomiting, phonophobia and photophobia. There were no 
important inter-group differences with respect to the onset of 
meaningful migraine relief, the frequency of headache recurrence, 
the usage or efficacy of a second dose of medication or the use 
of escape medicine.” However, the authors preceded to perform 
what they called a “post hoc analysis,” in which they found cer-
tain benefits to triptan use, including a greater overall patient 
satisfaction, overall pain-free reporting (as opposed to headache 
pain), a greater efficacy in patients with “migraine associated with 
menses,” and the fact that triptan use was “unaffected by age, 
weight, or gender.” They thus concluded that “Although evalua-
tion using the primary end point in this study was inconclusive, 
other end points such as freedom from pain, now identified as 
more clinically relevant end points, showed zolmitriptan 2.5 mg 
to be significantly better that the standard analgesic-anti-emetic 
combination of acetylsalicylic acid and metoclopramide.” In sum-
mary, this study found slight benefits to triptan use, although it is 
important to note that for all the primary end points designated 
before the study was completed, the therapies were identical. 
Only after the data was collected did the authors find certain 
benchmarks that could be identified as benefits to triptan use. 
This is generally considered a far less objective method of gath-
ering data, as it allows the investigator considerable latitude in 
actively picking specific data sets. In what may be an important 
note, the study concludes with an acknowledgement that “this 
study was supported by AstraZeneca Pharmaceuticals.” 
A third study, performed in New York City, compared aggressive 
metoclopramide treatment, consisting of four infusions within 
the first two hours, to subcutaneous sumatriptan treatment of 
migraine headaches (Friedman et. al., 2005). Two hundred two 
patients participated in the trial. Patients were not followed after 
the initial twenty-four-hour period, which can be considered a 
weakness in their overall assessment of the therapies; in fact, only 
37 of the patients completed the twenty four-hour follow-up 
protocol. In addition, the patient population studied was almost 
completely comprised of individuals of Latino origin, making ex-
trapolations to general populations uncertain. Another concern is 
that the study excluded those suffering chronic migraines, which 
may be a population which reacts differently to specific therapies. 
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The study concluded that there were no significant differences 
between the two therapy options in reaching the primary end 
points of the study, including headache relief, nausea relief, and 
overall well-being. However, in their own post hoc analysis, the 
authors find certain benefits to metoclopramide use, including 
twenty-four-hour symptom relief. 
A fourth comparative evaluation was performed in Iran at the 
Isfahan University of Medical Sciences, comparing metoclopr-
amide to sumatriptan for migraine headache treatment (Talabi 
et. al., 2013). This study was performed on emergency room 
patients. One hundred twenty-one subjects were included in 
this randomized, double-blind study. Several introductory notes 
should be mentioned about this study. First, the command of the 
English language displayed by the authors is competent overall 
but nevertheless displays signs of possible grammatical and idi-
omatic peculiarities which may or may not result in important, 
altered connotations (for example, the authors wrote that their 
study included a “controlled study design and patient blindness”). 
Second, the study noted that “it is surprising that no subjects in 
both groups complained of adverse effects.” This is a significant 
deviation from other comparable studies, which may be a cause 
for concern. The authors attempt to explain this discrepancy as 
“a result of slow metoclopramide injection and the way the ques-
tion about these effects were phrased.” It also may be a reflection 
of cultural differences in the way side effects are described, or 
how often, or upon what level of acuteness, they are remarked 
upon.  The patients were all observed during the initial hour after 
they were treated. The results of this trial were that metoclopr-
amide was superior to sumatriptan in headache relief (Talabi). 
In summary, there are very few studies that directly compare 
triptans to antiemetics for acute migraine headache relief. The 
few that have been performed suggest that the therapies are rel-
atively similar in effectivity for all primary end points. 
Triptans vs Antiemetics: Other Differences 
The fact that triptans and antiemetics have been shown to have 
similar outcomes in treating migraines does not necessarily mean 
that they are equally sound treatment options. In fact, there are 
several reasons why triptans may be a less advisable treatment 
option. The first is adverse effects. Triptans are known to cause 
several negative effects in patients. The most common set of ad-
verse side effects, affecting almost half of all triptan users, is often 
referred to as triptan sensations, and includes upper chest pres-
sure or pain and epithelial flushing. Rare cardiovascular events 
have also been reported and triptans are thus contraindicated in 
those with possible cardiac disease. This stands in contrast to an-
tiemetics, and specifically to metoclopramide, which have minimal 
reported adverse effects. The second shortcoming of triptans is 
their often high price, with the average cost of a single triptan pill 
typically exceeding ten dollars, while a single dose of antiemetics 
can cost less than ten cents (Adelman et. al., 2004). The benefits 
of antiemetics are thus both in terms of adverse effects, which 
are minimal, and cost, as they are extremely cheap therapy to 
provide to patients. Therefore, if antiemetics can be shown to 
be comparably effective to triptans in specific clinical settings, 
which seems to be the case, they can plausibly be considered 
a superior therapy overall under those conditions. Thus it re-
mains puzzling how the 2002 review article in the New England 
Journal of Medicine completely omitted antiemetics in its review 
of migraine relief protocols, and why it is omitted from the rec-
ommendations of the American Academy of Neurology on the 
treatment of migraines. 
Medical Parochialism
Parochialism in research has been a phenomenon long noted and 
lamented by meta-researchers (March, 2005). It is often based 
on nationality, with different countries’ research communities 
favoring different approaches. These differences can have cultural, 
ideological, or experiential origins. Parochialism can also be of 
disciplinary origin. In the medical field, this has often been the 
case; for example, medical doctors and nurse practitioners often 
find themselves at odds over a variety of disciplinary differences 
(Phillips et. al., 2002). In the specific case of the triptan vs. anti-
emetic debate, the difference in recommendations may have aris-
en from the different perspectives that neurologists and emer-
gency medicine doctors have of migraine sufferers. Emergency 
medicine practitioners generally see patients who are in the midst 
of acute migraine attacks. Therefore, their perspective is geared 
toward therapies that are most efficacious at immediate migraine 
relief, and this may factor into their preference of antiemetics to 
triptans (Friedman et. al., 2014). Neurologists, on the other hand, 
see mostly patients who are chronic migraine sufferers, and may 
therefore strongly favor treatments that provide longer-lasting 
relief. Nevertheless, it must be emphasized that the review in 
the New England Journal of Medicine was a complete review of 
both acute and chronic migraine treatments, and thus explicitly 
included the medical protocols in which emergency medicine 
practitioners are most experienced. It is therefore quite possible 
that parochialism is at fault for the varying guidelines proposed to 
treat migraines, where one field’s inherent biases led it to ignore 
or be unfamiliar with the practices of other fields. (It should be 
noted, however, that the 2005 study that found that antiemetics 
were comparable to triptans was authored by emergency room 
doctors and was published in the journal Neurology.)
Pharmaceutical Funding
Surveying the comparative studies of triptans and antiemetics 
brings to the fore the often uncomfortable question of relation-
ships between for-profit companies and medical institutions and 
research facilities (Smith, 2003). Although many regulations have 
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been passed over the last few decades, which have helped pre-
vent the more egregious practices of pharmaceutical companies, 
many interactions remain that might possibly compromise clinical 
objectivity (Brody, 2005). It is certain that drug companies would 
favor the use of expensive, patented triptans over the cheap an-
tiemetic drugs, and it is thus distressing that a drug company was 
the primary funder of the single comparative study that found, in 
post hoc data examination, that triptans were a superior treat-
ment option. The other studies were free of any reportable con-
flict of interest, and came to different conclusions. In addition, the 
review article from the New England Journal of Medicine, which 
strongly focused on and recommended triptan use, closes with 
a fine-print disclosure that all the authors have been recipients 
of grant funding or have acted as consultants for many different 
drug companies, including all those that currently manufacture 
triptan medications (Newman, 2009). This fact may explain why 
the authors, consciously or not, were especially focused on trip-
tan therapy. Of course, this does not mean to slander the authors 
in any way or to impugn their professional reputation, but rather 
to bring into focus the problems associated with industry funding 
of scientific enterprises. Certainly, the fact that such funding is 
indispensable to many research projects cannot be ignored, but 
perhaps other remedies, such as the mandatory authorship of 
one author without reportable conflicts of interest, can be ad-
vanced to protect the integrity of these studies. 
Another important question regarding pharmaceutical company 
funding of medical research is the types of studies performed. 
For example, if a pharmaceutical company deems a therapy to 
be dangerous toward its bottom line, it may simply withdraw all 
funding for studies pursuing that therapy, leaving little incentive 
for researchers to pursue it. This may explain why so few studies 
have actually been performed comparing triptans directly with 
almost any other therapy, including antiemetics, and instead most 
research in the field consists of large studies, including thousands 
of patients (Ferrari et. al., 2002), which look solely at the benefits 
of triptans. 
Conclusion
A survey of comparative studies available shows that antiemet-
ics are as suitable for treating acute migraines as triptans. The 
omission of this documented treatment from prominent guide-
lines and publications is disconcerting, and may point to several 
fundamental weaknesses in the current research and application 
model. Medical parochialism and pharmaceutical funding likely 
amplified these flaws, and must be addressed as part of the solu-
tion going forward. 
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